21 U.S. lawmakers have disclosed 72 Biogen Inc. trades under the STOCK Act — 48 buys and 24 sells between 2013 and 2026. Congress has been net buyers of BIIB, and their disclosed buys are up 7.1% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of BIIB, marked to the latest close — per-share (share counts aren't disclosed).
1 member disclosed a BIIB purchase in the last 90 days (newest first).
Lawmakers ranked by notional-weighted return on their disclosed BIIB buys (last ~3y), marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2015-08-04 | Sheldon Whitehouse | BUY | $1K–$15K | $330.38 | $210.65 2026-08-13 | -36.2% |
| 2015-08-04 | Sheldon Whitehouse | BUY | $1K–$15K | $330.38 | $210.65 2026-08-13 | -36.2% |
| 2015-07-31 | James B. Renacci | BUY | $1K–$15K | $318.78 | $210.65 2026-08-13 | -33.9% |
| 2015-07-30 | James B. Renacci | BUY | $1K–$15K | $317.00 | $210.65 2026-08-13 | -33.5% |
| 2015-07-23 | Alan S. Lowenthal | SELL | $1K–$15K | $385.05 | $210.65 2026-08-13 | -10.7% rt |
| 2015-07-10 | Sheldon Whitehouse | BUY | $1K–$15K | $388.23 | $210.65 2026-08-13 | -45.7% |
| 2015-07-09 | James M Inhofe | BUY | $15K–$50K | $399.29 | $210.65 2026-08-13 | -47.2% |
| 2015-05-12 | James B. Renacci | BUY | $1K–$15K | $395.30 | $210.65 2026-08-13 | -46.7% |
| 2015-05-07 | Sheldon Whitehouse | BUY | $15K–$50K | $383.29 | $210.65 2026-08-13 | -45.0% |
| 2015-05-07 | Sheldon Whitehouse | BUY | $15K–$50K | $383.29 | $210.65 2026-08-13 | -45.0% |
| 2015-05-06 | James B. Renacci | BUY | $1K–$15K | $383.56 | $210.65 2026-08-13 | -45.1% |
| 2015-04-15 | Alan S. Lowenthal | BUY | $15K–$50K | $430.96 | $210.65 2026-08-13 | -51.1% |
| 2015-04-07 | Sheldon Whitehouse | BUY | $1K–$15K | $418.09 | $210.65 2026-08-13 | -49.6% |
| 2015-03-30 | James B. Renacci | BUY | $1K–$15K | $431.62 | $210.65 2026-08-13 | -51.2% |
| 2015-03-20 | James B. Renacci | BUY | $1K–$15K | $475.98 | $210.65 2026-08-13 | -55.7% |
| 2014-12-02 | K. Michael Conaway | BUY | $1K–$15K | $328.27 | $210.65 2026-08-13 | -35.8% |
| 2014-07-23 | Susan M Collins | SELL | $1K–$15K | $337.60 | $210.65 2026-08-13 | +37.6% exit |
| 2014-07-23 | Susan M Collins | SELL | $1K–$15K | $337.60 | $210.65 2026-08-13 | +37.6% exit |
| 2014-03-27 | Susan M Collins | SELL | $1K–$15K | $309.76 | $210.65 2026-08-13 | +32.0% exit |
| 2013-06-05 | SUSAN M COLLINS | SELL | $1K–$15K | $214.10 | $210.65 2026-08-13 | +1.6% exit |
| 2013-06-04 | SUSAN M COLLINS | SELL | $1K–$15K | $219.74 | $210.65 2026-08-13 | +4.1% exit |
| James B. Renacci | BUY | $1K–$15K | — | — | — |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
21 members of the U.S. House and Senate have disclosed Biogen Inc. transactions under the STOCK Act — 48 purchases and 24 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
1 member disclosed a BIIB purchase in the last 90 days — most recently Gilbert Cisneros on 2026-06-05. See the "Lawmakers who bought BIIB recently" section above for the dated list.
Notional-weighted, lawmakers' disclosed BIIB buys are up 7.1% versus the latest close of $210.65. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded BIIB and how it performed.